US/UK/Canada

Share

Contacts

  • Malene Brondberg

    Chief Financial Officer


    1 Brassey Road, Old Potts Way, Shrewsbury SY3 7FA
    +47 22 18 33 01
    +44 7561 431 762
    http://www.nordicnanovector.com
    • Pick a time period -

    Nordic Nanovector to Discontinue PARADIGME, its Phase 2b Trial with Betalutin[®] in 3L R and R Follicular Lymphoma

    Webcast to be held at 08.30 CEST on Wednesday 6 JulyOslo, Norway, 5 July 2022 Nordic Nanovector ASA (OSE: NANOV) today provides an update on PARADIGME, its Phase 2b trial of Betalutin[® ]([177]Lu lilotomab satetraxetan) in 3[rd]-line relapsed and anti-CD20 refractory follicular lymphoma (3L R and R FL). Following a comprehensive review and independent data evaluation of PARADIGME and a subsequent request for regulatory agency interaction, the Board of Directors (Board) has taken the difficult decision to discontinue the study. No further patients will be enrolled into PARADIGME. The

    Nordic Nanovector to Seek Regulatory Feedback Following its Preliminary Review and Independent Data Evaluation of PARADIGME, its Phase 2b Trial with Betalutin® in R/R Follicular Lymphoma

    Oslo, Norway, 21 June 2022 Nordic Nanovector ASA (OSE: NANOV) today provides an update following its comprehensive review and independent data evaluation of PARADIGME, its ongoing Phase 2b trial of Betalutin[® ]([177]Lu lilotomab satetraxetan) in 3[rd]-line relapsed rituximab/anti-CD20 refractory follicular lymphoma (3L R/R FL). The independent expert panel reviewed the efficacy data collected to date. Betalutin®, at the selected dose of 15 MBq/kg after a pre-dose of 40 mg lilotomab (40/15), has continued to display an attractive safety profile. While Betalutin® showed signs of

    Nordic Nanovector Announces that the data from the LYMRIT 37-05 Phase 1 Trial of Betalutin® in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) will be presented at EHA 2022 Meeting

    Oslo, Norway, 10 June 2022 Nordic Nanovector ASA (OSE: NANOV) announces an update from the LYMRIT 37-05 Phase 1 trial investigating Betalutin® ([177]Lu lilotomab satetraxetan) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) not eligible for stem cell transplantation. The latest data to be presented at the European Hematology Association (EHA) Congress in Vienna, Austria on 10 June 2022 shows that Betalutin® continues to be well tolerated with no further dose-limiting toxicity (DLT). The data analysis showed that clinical activity of Betalutin® was seen

    Nordic Nanovector to Conduct a Comprehensive Review and Independent Data Evaluation of PARADIGME, its Phase 2b Trial with Betalutin® in R/R FL as a Result of Continuing Slow Recruitment

    Oslo, Norway, 2 June 2022 Nordic Nanovector ASA (OSE: NANOV) today provides an update on PARADIGME, its ongoing Phase 2b trial of Betalutin[® ]([177]Lu lilotomab satetraxetan) in 3[rd]-line relapsed rituximab/anti-CD20 refractory follicular lymphoma (3L R/R FL). As highlighted at the recent Q1 results, reported on 13 May 2022, recruitment into PARADIGME has been slower than anticipated, and despite ongoing efforts by the company this has continued into Q2 with no additional patients enrolled in May. As a result, the Board of Nordic Nanovector has decided to conduct a comprehensive

    Nordic Nanovector ASA: Allocation of restricted stock units (RSUs) to the board of directors

    Oslo, Norway, 20 May 2022 Reference is made to the minutes from Nordic Nanovector ASA's (the "Company") (OSE: NANOV) annual general meeting held on 28 April 2022 in Oslo, Norway (the "AGM"). At the AGM, the shareholders approved the issuance of restricted stock units ("RSUs") to board members who elect to receive all or parts of their remuneration, for the period from the annual general meeting in 2022 to the annual general meeting in 2023, in the form of RSUs.   The RSUs are non-transferable and each RSU give the right and obligation to acquire one share in the Company at a price

    Nordic Nanovector ASA: Results for the First Quarter 2022

    Oslo, Norway, 13 May 2022 Nordic Nanovector ASA (OSE: NANOV) announces its results for the first quarter 2022. A presentation by Nordic Nanovector’s senior management team will be held in-person today in Oslo and webcast live beginning at 8:30am CET – details below. Erik Skullerud, CEO of Nordic Nanovector, said: “The impacts from COVID-19 continued to linger during Q1 and meant the pick-up in recruitment into PARADIGME that we expected has not yet materialised. Nonetheless, we remain highly committed to completing patient recruitment for this important trial and expect to meet our

    Nordic Nanovector ASA: Invitation to First Quarter 2022 Results Presentation and Webcast

    Oslo, Norway, 6 May 2022 Nordic Nanovector ASA (OSE: NANOV) announces that it will report its results for the first quarter 2022 on Friday, 13 May 2022. A presentation by Nordic Nanovector's senior management team will be held in-person and webcast live beginning at 8:30am CET. Venue: Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo Meeting Room: Bjørvika The webcast can be accessed from www.nordicnanovector.com in the section: Investors & Media and a recording will also be available on this page after the event. The results report and the presentation will be

    Nordic Nanovector: New Publication Highlights Synergistic Potential of CD37-targeted Radioimmunoconjugate Humalutin® in Combination with the PARP-inhibitor Olaparib

    Second publication reports on CD37-targeting imaging approach to select NHL patients who might respond best to Humalutin® treatmentOslo, Norway, 3 May 2022 Nordic Nanovector ASA (OSE: NANOV), a clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune diseases, announces the publication of two new research papers highlighting approaches to improve the potential therapeutic effect of its novel CD37-targeting radioimmunoconjugate Humalutin® ([177]Lu-DOTA-NNV003) in B-cell malignancies, such as Non-Hodgkin Lymphoma (NHL). The first

    Nordic Nanovector ASA: The Annual General Meeting held

    Oslo, Norway, 28 April 2022 The Annual General Meeting (the “AGM”) of Nordic Nanovector ASA (the "Company") (OSE: NANOV) was held today on 28 April 2022 in Oslo, Norway. All proposals were resolved by the AGM as presented in the notice convening the AGM distributed on 6 April 2022. The complete minutes of the AGM are attached to this release, and are available on www.nordicnanovector.com. For further information, please contact: IR enquiries Malene Brondberg, CFOCell: +44 7561 431 762Email: ir@nordicnanovector.com Media Enquiries Mark Swallow/Frazer Hall (MEDiSTRAVA

    Nordic Nanovector ASA – Notice of Annual General Meeting on 28 April 2022

    Oslo, Norway, 6 April 2022 Notice is given that the Annual General Meeting of Nordic Nanovector ASA will be held on 28 April 2022, at 14:00 hours CEST at Advokatfirmaet Selmer, Tjuvholmen Allé 1, 0252 Oslo. The full notice with appendices and the recommendation from the Nomination Committee are attached. The notice and the documents to which it refers are also available on www.nordicnanovector.com. Shareholders wishing to attend the Annual General Meeting, in person or by proxy, must complete and return the attendance form or power of attorney form attached to the notice to Nordea

    Nordic Nanovector ASA publishes Annual Report 2021

    Oslo, Norway, 6 April 2022 On 5 April 2022, the Board of Directors of Nordic Nanovector ASA approved the Company's financial statements for 2021. The Company's 2021 Annual Report and ESEF file are attached.  The reports are also available on Nordic Nanovector ASA's website: www.nordicnanovector.com For further information, please contact: IR enquiries Malene Brondberg, CFOCell: +44 7561 431 762Email: ir@nordicnanovector.com Media Enquiries Mark Swallow/Frazer Hall (MEDiSTRAVA Consulting)Tel: +44 203 928 6900Email: nordicnanovector@medistrava.com About Nordic

    Nordic Nanovector ASA Announces Proposed Board Changes – Former Algeta CEO Thomas Ramdahl nominated to Join Board of Directors

    Oslo, Norway, 6 April 2022 Nordic Nanovector ASA (OSE: NANOV) announces that its Nomination Committee has nominated Dr Thomas Ramdahl for election as a Non-executive Director at the Company's Annual General Meeting (AGM) on 28 April 2022.  Dr Ramdahl is a pharmaceutical executive with more than 20 years of clinical and development experience. In 2001, he became President and first CEO of Algeta ASA, a Norwegian biotech company that successfully developed and launched a radiopharmaceutical for prostate cancer. During his time at Algeta, the company successfully completed Phase 1 and

    Nordic Nanovector ASA - Share capital increase registered

    Oslo, Norway, 25 March 2022 Reference is made to the stock exchange announcement made by Nordic Nanovector ASA (OSE: NANOV) (the "Company") on 23 March 2022 regarding the settlement of 42,675 PSUs. The share capital increase pertaining to the settled PSUs has now been registered in the Norwegian Register of Business Enterprises (the "NRBE") on 25 March 2022. The Company's share capital has been increased with NOK 8,535 through the issuance of 42,675 new shares. Following registration of the share capital increase related to the new shares in the NRBE, the Company has an issued

    Nordic Nanovector ASA – Mandatory notification of trade – settlement of PSUs

    Oslo, Norway, 23 March 2022 Reference is made to the stock exchange announcement made by Nordic Nanovector ASA's (OSE: NANOV) (the "Company") on 31 January 2019, regarding allocation of 259,000 PSUs to employees in accordance with the authorisation granted at the Company’s annual general meeting held 30 May 2018 (the “2018 AGM”). Each vested PSU will give the holder the right to receive one share in the Company at an exercise price corresponding to the par value of the shares being NOK 0.20. The total program ended at 42,675 vested PSUs which were exercised on 22 March 2022. Out of

    Nordic Nanovector ASA - Share capital increase registered

    Oslo, Norway, 22 March 2022 Reference is made to the stock exchange announcement on 14 March 2022 regarding the final result of Nordic Nanovector ASA's (OSE: NANOV) (the "Company") subsequent offering where 57,100 new shares (the "New Shares") were allocated at a subscription price of NOK 14 per share (the "Subsequent Offering"). The share capital increase pertaining to the Subsequent Offering has now been registered in the Norwegian Register of Business Enterprises (the "NRBE") on 22 March 2022. The Company's share capital has been increased with NOK 11,420 through the issuance of

    Nordic Nanovector ASA - Final results of the subsequent offering

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, SOUTH AFRICA, NEW ZEALAND, JAPAN OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL Oslo, Norway, 14 March 2022 Reference is made to the stock exchange announcement from Nordic Nanovector ASA (the "Company") dated 24 February 2022 relating to the subsequent offering and listing of up to 3,571,429 new shares, each with a nominal value of NOK 0.20 (the "

    Nordic Nanovector ASA - Preliminary results of the subsequent offering

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, SOUTH AFRICA, NEW ZEALAND, JAPAN OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL Oslo, Norway, 11 March 2022 Reference is made to the stock exchange announcement from Nordic Nanovector ASA (the "Company") dated 19 January 2022 relating to the subsequent offering and listing of up to 3,571,429 new shares, each with a nominal value of NOK 0.20 (the "

    Nordic Nanovector ASA – allocation of PSUs

    Oslo, Norway, 11 March 2022 The Board of Directors of Nordic Nanovector ASA ("Nordic Nanovector" or the "Company") has on 10 March 2022 decided to grant 934,000 Performance Share Units ("PSUs") to employees in accordance with the authorisation granted at the Annual General Meeting held on 28 April 2021 (the "AGM"). The terms and conditions of the PSUs, which are part of the Company's long-term incentive plan for employees, are described on pages 25-28 in the Company's annual report for 2020. The PSUs are granted without consideration. The PSUs are non-transferable and will vest

    Nordic Nanovector Announces Presentation of Preclinical Data on Alpha37, at the American Association for Cancer Research 2022 Annual Meeting

    Oslo, Norway, 9 March 2022 Nordic Nanovector ASA (OSE: NANOV), a clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune diseases, announces that an E-poster regarding Alpha37, entitled “Targeted alpha therapy with [212]Pb-NNV003 in treatment of NHL”, will be presented at the 2022 American Association of Cancer Research (AACR) Annual Meeting held 8-13 April in New Orleans, USA. The data in the E-poster show that a single injection of [212]Pb-NNV003, or Alpha37, is safe and effective for the treatment of CD37-positive chronic lymphocytic

    Nordic Nanovector ASA: Results for the Fourth Quarter and Full Year 2021

    Oslo, Norway, 01 March 2022 Nordic Nanovector ASA (OSE: NANOV) announces its results for the fourth quarter and full year 2021. A live webcast presentation by Nordic Nanovector’s management team will take place today at 08.30 CET at Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo, meeting room Bjørvika. A link to the webcast and the presentation is available from the Company's homepage (www.nordicnanovector.com). Erik Skullerud, Chief Executive Officer of Nordic Nanovector, commented: “The fourth quarter was a productive period for the Company as we continued to drive PARADIGME

    Nordic Nanovector ASA - Commencement of the subscription period in the subsequent share offering

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, SOUTH AFRICA, NEW ZEALAND, JAPAN OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL Nordic Nanovector ASA - Commencement of the subscription period in the subsequent share offering Oslo, Norway, 28 February 2022 Reference is made to the stock exchange announcement from Nordic Nanovector ASA ("Nordic Nanovector" or the "Company") published on 19

    Nordic Nanovector ASA: Prospectus approved

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, SOUTH AFRICA, NEW ZEALAND, JAPAN OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL Nordic Nanovector ASA: Prospectus approved Oslo, Norway, 24 February 2022 Reference is made to the stock exchange announcements on 19 January 2022 where Nordic Nanovector ASA (the "Company") announced that the Company had carried out a successful private placement

    Nordic Nanovector ASA - Resolution to increase the share capital in connection with the subsequent offering and terms of the subsequent offering

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, SOUTH AFRICA, NEW ZEALAND, JAPAN OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL Nordic Nanovector ASA - Resolution to increase the share capital in connection with the subsequent offering and terms of the subsequent offering Oslo, Norway, 24 February 2022 Reference is made to the stock exchange announcement from Nordic Nanovector ASA ("Nordic

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe